Trenton, NJ – According to Seth Augenstein of Bioscience Technology, “Alzheimer’s is feared for its quiet progress, giving only overlooked warning signs until it’s too late to use the few interventions available to slow it down."
"But a new test under development at a New Jersey medical laboratory promises to diagnose the earliest stages of Alzheimer’s.
Robert Nagele, of the Rowan University School of Osteopathic Medicine, has developed a test that looks for a series of obscure antibodies, potentially detecting the dreaded disease even before symptoms start.
Nagele presented the latest results on Sunday at the American Osteopathic Association’s yearly meeting in Orlando.
“There are significant benefits to early-disease detections because we now know that many of the same conditions that lead to vascular disease are also significant risk factors for Alzheimer’s,” said Nagele. “People found to have preclinical disease can take steps to improve their vascular health, including watching their diet, exercising and managing any weight and blood-pressure issues to help stave off or slow disease progression.
Nagele’s working theory of diagnostics is based off auto-antibodies in the blood. All humans have thousands of them, and the biomarkers are a response to disease and injury over a lifetime. A full cataloging of those biomarkers could be the key to determining whether disease is silently developing."
For the full story: http://www.biosciencetechnology.com/news/2015/10/nj-researchers-closing-alzheimers-parkinsons-tests?et_cid=4891408&et_rid=45516965&type=cta
Robert Nagele, of the Rowan University School of Osteopathic Medicine, has developed a test that looks for a series of obscure antibodies, potentially detecting the dreaded disease even before symptoms start.
Nagele presented the latest results on Sunday at the American Osteopathic Association’s yearly meeting in Orlando.
“There are significant benefits to early-disease detections because we now know that many of the same conditions that lead to vascular disease are also significant risk factors for Alzheimer’s,” said Nagele. “People found to have preclinical disease can take steps to improve their vascular health, including watching their diet, exercising and managing any weight and blood-pressure issues to help stave off or slow disease progression.
Nagele’s working theory of diagnostics is based off auto-antibodies in the blood. All humans have thousands of them, and the biomarkers are a response to disease and injury over a lifetime. A full cataloging of those biomarkers could be the key to determining whether disease is silently developing."
For the full story: http://www.biosciencetechnology.com/news/2015/10/nj-researchers-closing-alzheimers-parkinsons-tests?et_cid=4891408&et_rid=45516965&type=cta
